MedTrace Logo

Hear Me Read 2021 Clinical Trial

NCT05245799 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the effects of in-person speech-language therapy with a novel digital storybook intervention platform (Hear Me Read) improves vocabulary, speech and language, and literacy outcomes in young children who are deaf or hard of hearing compared with in-person therapy alone.

Conditions

  • Hearing Loss
  • Deafness
  • Hearing Disorders in Children
  • Hearing Impaired Children
  • Speech Therapy
  • Speech Disorders in Children
  • Literacy

Interventions

BEHAVIORAL

Speech Language Therapy

Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.

BEHAVIORAL

Digital Software Application

The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.

Sponsors & Collaborators

  • Clinical and Translational Intramural Funding Program from the Abigail Wexner Research Institute

    collaborator UNKNOWN

  • Prasanth Pattisapu

    lead OTHER

Principal Investigators

  • Prasanth Pattisapu, MD · Nationwide Children's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2024-03-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245799 on ClinicalTrials.gov